34 Participants Needed

Neuromodulation for Schizophrenia

PG
Overseen ByPhillip Gerretson, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Scion NeuroStim
Must be taking: Antipsychotics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to help people with schizophrenia better understand and manage their illness. It employs a safe, non-invasive brainstem modulation device to gently stimulate the brainstem and track brain changes using imaging. The trial includes different groups testing various stimulation patterns. Suitable participants have schizophrenia or schizoaffective disorder and struggle with understanding their illness despite stable medication use. As an unphased trial, it offers a unique opportunity for participants to contribute to innovative research that could lead to new insights and treatments.

Will I have to stop taking my current medications?

The trial requires that participants have been on a stable dose of their antipsychotic and other medications for at least 2 months before joining, and they should not expect to change doses during the study.

What prior data suggests that this neuromodulation device is safe for schizophrenia?

Research shows that non-invasive brainstem modulation is generally safe, stimulating the brainstem without surgery or other invasive methods. Most participants tolerate it well and experience no serious side effects.

In past studies of similar techniques, such as transcranial magnetic stimulation, some participants reported minor side effects, including mild headaches or slight discomfort at the stimulation site. However, these effects typically resolve quickly on their own.

As this treatment remains under study, some unknown risks may exist. However, its non-invasive nature suggests it is likely safe. Those considering joining a trial will be closely monitored by the healthcare team to ensure safety.12345

Why are researchers excited about this trial?

Researchers are excited about neuromodulation for schizophrenia because it offers a non-invasive approach to treatment, unlike traditional antipsychotic medications that often come with a range of side effects. This treatment uses a brainstem modulation device, which directly targets neural pathways involved in schizophrenia, potentially leading to more precise and effective management of symptoms. By focusing on specific brain regions rather than altering chemical balances throughout the entire brain, this method could minimize side effects and improve patient outcomes significantly. Additionally, the non-invasive nature of the treatment could make it more accessible and less intimidating for patients compared to current standard treatments like antipsychotic drugs or electroconvulsive therapy.

What evidence suggests that this neuromodulation device is effective for schizophrenia?

Research has shown that using a non-invasive device on the brainstem might alleviate symptoms of schizophrenia, particularly by enhancing patients' understanding of their illness. A review of several studies has found that different non-invasive brain stimulation methods can effectively treat the negative symptoms of schizophrenia. Another review highlighted that these techniques might improve social skills in people with the condition. Additionally, a study with 644 patients demonstrated that non-invasive brain stimulation improved negative symptoms. In this trial, participants will receive one of the investigational stimulation patterns using the brainstem modulation device. These findings suggest that the brainstem modulation device under study could increase illness awareness and possibly improve treatment outcomes for schizophrenia.15678

Are You a Good Fit for This Trial?

This trial is for adults over 18 with schizophrenia or schizoaffective disorder, who have trouble recognizing their illness. They must speak English, be on stable medication for two months, and able to consent. Excluded are those with recent eye surgery, ear infections, substance dependence (except caffeine/nicotine), metal implants/pacemakers affecting MRI scans, pregnancy, vestibular dysfunction, severe medical conditions or thought disorders.

Inclusion Criteria

Moderate-to-severe lack of illness awareness ≤7 on the VAGUS-SR, which corresponds to a rating of ≥3 on PANSS G12 Insight and Judgment item
Fluent in English
I am willing and able to agree to participate in this study.
See 2 more

Exclusion Criteria

Unwilling or unable to consent to the study
I use hearing aids or have chronic ear problems.
Metal implants or a pacemaker that would preclude the MRI scan
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive brainstem neuromodulation using an investigational study device, with neuroimaging to measure brain changes

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Non-invasive brainstem modulation device
Trial Overview The study tests a non-invasive brainstem modulation device's effect on illness awareness in schizophrenia patients. It involves safe brain stimulation alongside neuroimaging to track changes in the brain related to treatment response and recognition of the illness.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Group I: Investigational Stimulation Pattern-Open LabelExperimental Treatment1 Intervention
Group II: Investigational Stimulation Pattern 2-RandomizedExperimental Treatment1 Intervention
Group III: Investigational Stimulation Pattern 1-RandomizedExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Scion NeuroStim

Lead Sponsor

Trials
14
Recruited
550+

Centre for Addiction and Mental Health

Collaborator

Trials
388
Recruited
84,200+

Published Research Related to This Trial

Recent randomized-controlled trials indicate that noninvasive brain stimulation can provide long-lasting relief from symptoms in patients with treatment-resistant schizophrenia.
Innovative stimulation techniques, such as theta burst stimulation and new electrical methods, have shown promising results, suggesting that optimizing stimulation parameters could enhance treatment efficacy for schizophrenia.
Recent advances in noninvasive brain stimulation for schizophrenia.Brunelin, J., Adam, O., Mondino, M.[2023]
Repetitive transcranial magnetic stimulation (rTMS) has a significant effect on reducing negative symptoms in schizophrenia, with a mean effect size of 0.64 based on 22 studies involving 827 participants, indicating it is more effective than sham stimulation.
Transcranial direct current stimulation (tDCS) also shows promise, with a mean effect size of 0.50 from 5 studies with 134 participants, but the evidence is less robust compared to rTMS, suggesting that more research is needed to fully understand its efficacy.
Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials.Aleman, A., Enriquez-Geppert, S., Knegtering, H., et al.[2019]
A study involving 20 stable schizophrenia patients tested the safety and efficacy of transcutaneous vagus nerve stimulation (tVNS) over 26 weeks, finding that the treatment was well tolerated with no significant adverse effects.
However, the study did not show a statistically significant improvement in schizophrenia symptoms compared to sham stimulation, suggesting that while tVNS is safe, it may not be effective for this condition in the current trial setup.
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.Hasan, A., Wolff-Menzler, C., Pfeiffer, S., et al.[2018]

Citations

NCT05580211 | Neuromodulation for SchizophreniaStudy participants will receive ~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
Assessment of Noninvasive Brain Stimulation Interventions for ...This meta-analysis compares the efficacy and acceptability of different noninvasive brain stimulation interventions for treating negative ...
Neuromodulation in the treatment of social cognition ...This systematic review evaluates the use of neuromodulation techniques in treating social cognition deficits in schizophrenia.
Efficacy and safety of non-invasive brain stimulation on ...Fourteen studies with 644 schizophrenia patients provided PANSS negative symptoms improvement data. The pooled results demonstrated that the effect of NIBS ...
Neuromodulation for SchizophreniaThe non-invasive brainstem modulation device is unique because it uses non-invasive brain stimulation to potentially improve symptoms of schizophrenia by ...
Neuromodulation for SchizophreniaThe study device under investigation provides a safe and non-invasive method of brainstem stimulation that will be used in conjunction with ...
Neuromodulation techniques – From non-invasive brain ...Neuromodulation can be delivered through a variety of means, including non-invasive modalities such as transcranial magnetic stimulation (TMS), transcranial ...
The Effects of Non-invasive Neuromodulation on Illness ...The proposed study employs a novel approach to determine the clinical and functional imaging effects of CVS on illness awareness in schizophrenia - a ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security